Literature DB >> 30285055

Divergent Long-Term Detection Rates of Proximal and Distal Advanced Neoplasia in Fecal Immunochemical Test Screening Programs: A Retrospective Cohort Study.

Manuel Zorzi1, Cesare Hassan2, Giulia Capodaglio3, Elena Narne4, Anna Turrin4, Maddalena Baracco1, Antonella Dal Cin1, Annarita Fiore1, Giancarla Martin1, Alessandro Repici5, Douglas Rex6, Massimo Rugge7.   

Abstract

Background: Short-term studies have reported that the fecal immunochemical test (FIT) is less accurate in detecting proximal than distal colorectal neoplasia. Objective: To assess the long-term detection rates for advanced adenoma and colorectal cancer (CRC), according to anatomical location. Design: Retrospective study. Setting: Population-based, organized screening program in the Veneto region of Italy. Participants: Persons aged 50 to 69 years who completed 6 rounds of FIT screening. Measurements: At each screening round, the detection rates for advanced adenoma and cancer, as well as the proportional interval cancer rate (PICR), were calculated by anatomical location (proximal colon, distal colon, or rectum).
Results: Between 2002 and 2014, a total of 123 347 participants had 441 647 FITs. The numbers of advanced adenomas and cancer cases detected, respectively, were 1704 and 200 in the proximal colon, 3703 and 324 in the distal colon, and 1220 and 209 in the rectum. Although the detection rate for proximal colon cancer declined only from the first to the second screening round (0.63 to 0.36 per 1000 screenees), the rate for both distal colon and rectal cancer steadily decreased across 6 rounds (distal colon, 1.65 in the first round to 0.17 in the sixth; rectum, 0.82 in the first round to 0.17 in the sixth). Similar trends were found for advanced adenoma (proximal colon, 5.32 in the first round to 4.22 in the sixth; distal colon, 15.2 in the first round to 5.02 in the sixth). Overall, 150 cases of interval cancer were diagnosed. The PICR was higher in the proximal colon (25.2% [95% CI, 19.9% to 31.5%]) than the distal colon (6.0% [CI, 3.9% to 8.9%]) or rectum (9.9% [CI, 6.9% to 13.7%]). Limitations: Participants with irregular attendance were censored. Those who had a false-positive result on a previous FIT but negative colonoscopy results were included in subsequent rounds.
Conclusion: This FIT-based, multiple-round, long-term screening program had a negligible reduction in detection rates for neoplastic lesions in the proximal versus the distal colon after the first round. This was related to a higher PICR in the proximal colon and suboptimal efficacy in preventing the age-related proximal shifting of CRC. Primary Funding Source: None.

Entities:  

Mesh:

Year:  2018        PMID: 30285055     DOI: 10.7326/M18-0855

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  8 in total

1.  American Indian/Alaska Native and black colon cancer patients have poorer cause-specific survival based on disease stage and anatomic site of diagnosis.

Authors:  V Shane Pankratz; Mikaela Kosich; Nicholas Edwardson; Kevin English; Prajakta Adsul; Yiting Li; Gulshan Parasher; Shiraz I Mishra
Journal:  Cancer Epidemiol       Date:  2022-07-21       Impact factor: 2.890

Review 2.  Guaiac-based faecal occult blood tests versus faecal immunochemical tests for colorectal cancer screening in average-risk individuals.

Authors:  Esmée J Grobbee; Pieter Ha Wisse; Eline H Schreuders; Aafke van Roon; Leonie van Dam; Ann G Zauber; Iris Lansdorp-Vogelaar; Wichor Bramer; Sarah Berhane; Jonathan J Deeks; Ewout W Steyerberg; Monique E van Leerdam; Manon Cw Spaander; Ernst J Kuipers
Journal:  Cochrane Database Syst Rev       Date:  2022-06-06

3.  Negative Impact of COVID-19 Associated Health System Shutdown on Patients Diagnosed With Colorectal Cancer: A Retrospective Study From a Large Tertiary Center in Ontario, Canada.

Authors:  Catherine L Forse; Stephanie Petkiewicz; Iris Teo; Bibianna Purgina; Kristina-Ana Klaric; Tim Ramsay; Jason K Wasserman
Journal:  J Can Assoc Gastroenterol       Date:  2021-12-16

4.  Value of Serum NEUROG1 Methylation for the Detection of Advanced Adenomas and Colorectal Cancer.

Authors:  Olalla Otero-Estévez; María Gallardo-Gomez; María Páez de la Cadena; Francisco Javier Rodríguez-Berrocal; Joaquín Cubiella; Vicent Hernandez Ramirez; Laura García-Nimo; Loretta De Chiara
Journal:  Diagnostics (Basel)       Date:  2020-06-28

5.  Interval cancers in a population-based screening program for colorectal cancer with gender-specific cut-off levels for fecal immunochemical test.

Authors:  Hanna Ribbing Wilén; Deborah Saraste; Johannes Blom
Journal:  J Med Screen       Date:  2022-03-08       Impact factor: 1.687

6.  Characteristics of Advanced Colorectal Cancer Detected by Fecal Immunochemical Test Screening in Participants with a Negative Result the Previous Year.

Authors:  Ryosuke Hasegawa; Kazuo Yashima; Yuichiro Ikebuchi; Shuji Sasaki; Akira Yoshida; Koichiro Kawaguchi; Hajime Isomoto
Journal:  Yonago Acta Med       Date:  2020-02-20       Impact factor: 1.641

7.  Long-term effectiveness of faecal immunochemical test screening for proximal and distal colorectal cancers.

Authors:  Han-Mo Chiu; Grace Hsiao-Hsuan Jen; Ying-Wei Wang; Jean Ching-Yuan Fann; Chen-Yang Hsu; Ya-Chung Jeng; Amy Ming-Fang Yen; Sherry Yueh-Hsia Chiu; Sam Li-Sheng Chen; Wen-Feng Hsu; Yi-Chia Lee; Ming-Shiang Wu; Chien-Yuan Wu; Yann-Yuh Jou; Tony Hsiu-Hsi Chen
Journal:  Gut       Date:  2021-01-25       Impact factor: 23.059

8.  Multitarget Stool DNA Screening in Clinical Practice: High Positive Predictive Value for Colorectal Neoplasia Regardless of Exposure to Previous Colonoscopy.

Authors:  Jason D Eckmann; Derek W Ebner; Jamie Bering; Allon Kahn; Eduardo Rodriguez; Mary E Devens; Kari L Lowrie; Karen Doering; Sara Then; Kelli N Burger; Douglas W Mahoney; David O Prichard; Michael B Wallace; Suryakanth R Gurudu; Lila J Finney; Paul Limburg; Barry Berger; David A Ahlquist; John B Kisiel
Journal:  Am J Gastroenterol       Date:  2020-04       Impact factor: 12.045

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.